HYPOALBUMINEMIA EARLY IN TREATMENT HINDERS BENEFIT FROM IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH ADVANCED CANCERS.

被引：0
|
作者：
Guo, Y. [1 ]
Kulp, S. [1 ]
Mace, T. [2 ]
Coss, C. [1 ]
Phelps, M. [1 ]
Owen, D. [2 ]
机构：
[1] Ohio State Univ, Columbus, OH 43210 USA
[2] James Canc Hosp, Columbus, OH USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2022年 / 111卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PT-006
引用
收藏
页码：S63 / S64
页数：2
相关论文
共 50 条
  • [1] Utility of circulating tumor DNA in monitoring treatment response to immune checkpoint inhibitors in patients with advanced genitourinary cancers.
    Jang, Albert
    Jaeger, Ellen B.
    Rauterkus, Grant
    Lieberman, Alexandra
    Huang, Minqi
    Lanka, Sree M.
    Sudhaman, Sumedha
    Mahmood, Tamara
    Pajak, Natalia
    Calhoun, Mark
    Tlemcani, Kaoutar
    ElNaggar, Adam
    Liu, Minetta
    Lewis, Brian E.
    Layton, Jodi Lyn
    Sartor, A. Oliver
    Barata, Pedro C.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [2] Treatment of advanced urogenital cancers with immune checkpoint inhibitors
    Jung, Eun Hee
    Kim, Se Hyun
    JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2021, 64 (05): : 349 - 357
  • [3] A plasma-based proteomic platform for predicting clinical benefit from immune checkpoint inhibitors in multiple cancers.
    Sela, Itamar
    Lahav, Coren
    Lowenthal, Gil
    Harel, Michal
    Elon, Yehonatan
    Yellin, Ben
    Dicker, Adam P.
    Halaban, Ruth
    Marte, Jenn
    Sznol, Mario
    Gulley, James L.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [4] Efficacy and toxicity of immunotherapy with immune checkpoint inhibitors in gynecologic cancers.
    Kuznicki, Michelle
    Joehlin-Price, Amy
    Rose, Peter Graham
    Mahdi, Haider
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [5] Efficacy of ramucirumab and docetaxel given either before or after immune checkpoint inhibitors in patients with lung cancers.
    Offin, Michael
    Xu, Chongrui
    Jain, Harsh
    Makhnin, Alex
    Hayes, Sara A.
    Plodkowski, Andrew J.
    Halpenny, Darragh
    Rudin, Charles M.
    Kris, Mark G.
    Drilon, Alexander E.
    Li, Bob T.
    Paik, Paul K.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [6] NF1 mutation as an indicator stratified patients benefit from immune checkpoint inhibitors in gastroesophageal cancers
    Xiao, H.
    Zhao, L.
    Xiao, M. Z.
    Qi, C.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S577 - S577
  • [7] Clinical Outcome and Benefit of Immune Checkpoint Inhibitors in Patients with Advanced Pulmonary Sarcomatoid Carcinoma
    Chang, C.
    Shih, J.
    Liao, W.
    Chen, K.
    Yang, C.
    Lee, J.
    Hsu, C.
    Yang, J.
    Yu, C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [8] Genetic ancestry and clinical outcomes to immune checkpoint inhibitors among seven common cancers.
    Nassar, Amin
    Adib, Elio
    Abou Alaiwi, Sarah
    Akl, Elie
    El Zarif, Talal
    Nuzzo, Pier Vitale
    Mouhieddine, Tarek H.
    El-Khoury, Habib
    Groha, Stefan
    Sonpavde, Guru P.
    Haddad, Robert I.
    Mouw, Kent William
    Giannakis, Marios
    Ananda, Guruprasad
    Freedman, Matthew L.
    Kwiatkowski, David J.
    MacConaill, Laura E.
    Choueiri, Toni K.
    Gusev, Alexander
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [9] Immune checkpoint inhibitors in patients with cancers of unknown primary
    Rassy, Elie
    Karam, Elias
    Adeleke, Sola
    Okoli, Somto
    Galante, Joao
    Boussios, Stergios
    Pavlidis, Nicholas
    EUROPEAN JOURNAL OF CANCER, 2023, 195
  • [10] Treatment-related toxicities of immune checkpoint inhibitors in advanced cancers: A meta-analysis
    Man, Johnathan
    Ritchie, Georgia
    Links, Matthew
    Lord, Sally
    Lee, Chee Khoon
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 (03) : 141 - 152
12345